Byetta Scripts, LAR Progress Unaffected By Safety Scare, Amylin Says

FDA's review of a new monotherapy indication for Amylin's type 2 diabetes agent Byetta (exenatide) may provide the opportunity for updating the labeling to reflect a stronger warning on pancreatitis